Kura Oncology (NASDAQ:KURA) Insider Sells $130,704.00 in Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Mollie Leoni sold 12,448 shares of the stock in a transaction that occurred on Monday, September 28th. The stock was sold at an average price of $10.50, for a total value of $130,704.00. Following the completion of the sale, the insider owned 169,897 shares in the company, valued at approximately $1,783,918.50. The trade was a 6.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Mollie Leoni also recently made the following trade(s):

• On Tuesday, September 29th, Mollie Leoni sold 28,802 shares of Kura Oncology stock. The shares were sold at an average price of $10.75, for a total value of $309,621.50.

Kura Oncology Trading Up 1.9%

KURA stock traded up $0.20 during midday trading on Tuesday, reaching $10.81. The company’s stock had a trading volume of 1,890,260 shares, compared to its average volume of 1,673,937. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73. The stock has a fifty day simple moving average of $11.22 and a two-hundred day simple moving average of $10.15. Kura Oncology, Inc. has a 1 year low of $7.36 and a 1 year high of $13.90. The firm has a market capitalization of $961.66 million, a price-to-earnings ratio of -3.21 and a beta of 0.44.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.11. The business had revenue of $20.87 million during the quarter, compared to the consensus estimate of $20.16 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. On average, equities research analysts predict that Kura Oncology, Inc. will post -3.25 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Wedbush boosted their price objective on shares of Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a research report on Thursday, August 13th. Morgan Stanley set a $24.00 target price on shares of Kura Oncology in a research report on Monday, August 24th. Wells Fargo & Company set a $24.00 price target on shares of Kura Oncology in a research note on Thursday, June 4th. Raymond James Financial set a $24.00 price objective on Kura Oncology in a research note on Monday, August 24th. Finally, Citigroup restated a “market outperform” rating on shares of Kura Oncology in a report on Monday, August 24th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $25.40.

Key Kura Oncology News

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: KO-7246 regenerated functional pancreatic beta-cell mass and improved glycemic control in Type 1 and Type 2 diabetes models. Benefits persisted for at least one month after treatment stopped in a Type 1 diabetes model, suggesting potential disease-modifying activity. KO-7246 EASD announcement
• Positive Sentiment: The candidate increased beta-cell mass, endogenous insulin and C-peptide levels, and showed enhanced activity when combined with semaglutide. Results in human pancreatic islets also indicated selective beta-cell proliferation and improved glucose-responsive insulin secretion, strengthening the potential commercial value of Kura’s menin-inhibitor platform. KO-7246 preclinical data
• Neutral Sentiment: KO-7246 remains preclinical. Caspian plans IND-enabling work and a future Phase 1 study, with management scheduled to discuss the program on October 13. Any valuation benefit for KURA therefore depends on future clinical progress and the terms of Kura’s relationship with Caspian. Caspian and Kura KO-7246 report
• Negative Sentiment: Several Kura executives and insiders sold shares on September 28–29, including Mollie Leoni, Brian Powl, Kathleen Ford, Thomas Doyle and Teresa Bair. The transactions totaled approximately 97,000 shares and more than $1 million, signaling near-term insider selling pressure even though the sellers retained substantial holdings. Kura insider ownership filing
• Negative Sentiment: The diabetes opportunity carries substantial execution risk, including potential clinical or regulatory setbacks, unexpected safety findings and the need for additional financing before human trials can begin.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Tidal Investments LLC bought a new stake in shares of Kura Oncology in the 2nd quarter valued at about $1,029,000. WINTON GROUP Ltd boosted its stake in shares of Kura Oncology by 26.2% during the second quarter. WINTON GROUP Ltd now owns 13,000 shares of the company’s stock valued at $143,000 after purchasing an additional 2,700 shares in the last quarter. Integrated Wealth Concepts LLC bought a new position in shares of Kura Oncology during the second quarter valued at approximately $159,000. IFP Advisors Inc increased its holdings in Kura Oncology by 136.5% during the second quarter. IFP Advisors Inc now owns 2,542 shares of the company’s stock valued at $28,000 after buying an additional 1,467 shares during the period. Finally, Allworth Financial LP grew its stake in Kura Oncology by 148.4% in the second quarter. Allworth Financial LP now owns 10,326 shares of the company’s stock valued at $113,000 after purchasing an additional 6,169 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.

Kura’s leading program has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia, including cancers with NPM1 mutations or certain KMT2A rearrangements.